NCT04611750View on ClinicalTrials.gov

Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Sleep Disordered Breathing
Interventions
DRUG

AD036

AD036 will be given for 14 days

DRUG

Placebo

Placebo will be given for 14 days

Trial Locations (2)

3168

Monash University, Clayton

02141

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Apnimed
All Listed Sponsors
collaborator

Apnimed

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT04611750 - Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing | Biotech Hunter | Biotech Hunter